. 2021 Oct 29;64(21):16159–16176. doi: 10.1021/acs.jmedchem.1c01437

Table 1. Current Portfolio of VL Drug Candidates in Clinical Development^a.

compound ID	compound class	mechanism of action and/or molecular target	organization
DNDI-6148⁶	benzoxaborole	CPSF3	DNDi/Pfizer
DNDI-0690⁶	nitroimidazole	bioactivation by NTR2⁷	DNDi/TB Alliance
GSK3186899/DDD853651^6,7	pyrazolopyrimidine	CRK12 (cyclin-dependent kinase)⁸	GSK/DDU
GSK3494245/DDD1305143^6,8	imidazopyridine	proteasome inhibitor⁹	GSK/DDU
LXE408⁹	triazolopyrimidine	proteasome inhibitor¹⁰	Novartis

DDU: Drug Discovery Unit, University of Dundee and GSK: GlaxoSmithKline.

Table 1. Current Portfolio of VL Drug Candidates in Clinical Developmenta.